Hochhaus, A
Rosti, G
Cross, N C P
Steegmann, J L
le Coutre, P
Ossenkoppele, G
Petrov, L
Masszi, T
Hellmann, A
Griskevicius, L
Wiktor-Jedrzejczak, W
Rea, D
Coriu, D
Brümmendorf, T H
Porkka, K
Saglio, G
Gastl, G
Müller, M C
Schuld, P
Di Matteo, P
Pellegrino, A
Dezzani, L http://orcid.org/0000-0003-2047-2526
Mahon, F-X
Baccarani, M
Giles, F J
Article History
Received: 9 July 2015
Revised: 14 September 2015
Accepted: 18 September 2015
First Online: 6 October 2015
Competing interests
: Authors declare the following relationships with pharmaceutical companies: Novartis—receipt of honoraria (AHo, GR, NC, JS, PlC, TM, LG, WWJ, DR, DC, TB, GS, MM, FXM, MB, FG), research funding (all authors), nonfinancial support (GR, WWJ, DC, TB), employment (PS, PDM, AP, LD) and stock ownership (PS); Pfizer—receipt of honoraria (AHo, GR, JS, PlC, DR, DC, TB, GS, FXM, MB), research funding (AHo, GR, JS, TB) and nonfinancial support (GR, TB); Ariad—receipt of honoraria (AHo, GR, NC, JS, PlC, DR, TB, GS, MM, FXM, MB), research funding (AHo, GR, JS, MM) and nonfinancial support (GR, TB); Bristol-Myers Squibb—receipt of honoraria (AHo, GR, JS, PlC, TM, DR, DC, TB, GS, MM, FXM, MB), research funding (AHo, GR, JS, MM) and nonfinancial support (GR, TB).